Next Article in Journal
A Phase 1 Study of mTORC1/2 Inhibitor BI 860585 as a Single Agent or with Exemestane or Paclitaxel in Patients with Advanced Solid Tumors
Previous Article in Journal
Surveillance for Hepatocellular Carcinoma in Patients with Non-Alcoholic Fatty Liver Disease: Universal or Selective?
Open AccessReview

Patient-Derived In Vitro Models for Drug Discovery in Colorectal Carcinoma

1
Molecular Pharmacology Group, School of Pharmaceutical Sciences, Institute of Pharmaceutical Sciences of Western Switzerland, University of Geneva, 1211 Geneva, Switzerland
2
Translational Research Center in Oncohaematology, University of Geneva, 1211 Geneva, Switzerland
3
Department of Oncology, Geneva University Hospitals, 1211 Geneva, Switzerland
4
Division of Clinical Pathology, Diagnostic Department, University Hospitals of Geneva (HUG), 1211 Geneva, Switzerland
5
Translational Department of Digestive and Transplant Surgery, Faculty of Medicine, Geneva University Hospitals, 1211 Geneva, Switzerland
*
Author to whom correspondence should be addressed.
Cancers 2020, 12(6), 1423; https://doi.org/10.3390/cancers12061423
Received: 3 May 2020 / Revised: 26 May 2020 / Accepted: 28 May 2020 / Published: 31 May 2020
Lack of relevant preclinical models that reliably recapitulate the complexity and heterogeneity of human cancer has slowed down the development and approval of new anti-cancer therapies. Even though two-dimensional in vitro culture models remain widely used, they allow only partial cell-to-cell and cell-to-matrix interactions and therefore do not represent the complex nature of the tumor microenvironment. Therefore, better models reflecting intra-tumor heterogeneity need to be incorporated in the drug screening process to more reliably predict the efficacy of drug candidates. Classic methods of modelling colorectal carcinoma (CRC), while useful for many applications, carry numerous limitations. In this review, we address the recent advances in in vitro CRC model systems, ranging from conventional CRC patient-derived models, such as conditional reprogramming-based cell cultures, to more experimental and state-of-the-art models, such as cancer-on-chip platforms or liquid biopsy. View Full-Text
Keywords: colorectal cancer; organoids; 3D bioprinting; patient-derived xenograft; cancer-on-chip; drug combination colorectal cancer; organoids; 3D bioprinting; patient-derived xenograft; cancer-on-chip; drug combination
Show Figures

Figure 1

MDPI and ACS Style

Ramzy, G.M.; Koessler, T.; Ducrey, E.; McKee, T.; Ris, F.; Buchs, N.; Rubbia-Brandt, L.; Dietrich, P.-Y.; Nowak-Sliwinska, P. Patient-Derived In Vitro Models for Drug Discovery in Colorectal Carcinoma. Cancers 2020, 12, 1423.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop